196 related articles for article (PubMed ID: 29171155)
1. Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine.
Lilius TO; Viisanen H; Jokinen V; Niemi M; Kalso EA; Rauhala PV
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):481-488. PubMed ID: 29171155
[TBL] [Abstract][Full Text] [Related]
2. Ketamine and norketamine attenuate oxycodone tolerance markedly less than that of morphine: from behaviour to drug availability.
Lilius T; Kangas E; Niemi M; Rauhala P; Kalso E
Br J Anaesth; 2018 Apr; 120(4):818-826. PubMed ID: 29576122
[TBL] [Abstract][Full Text] [Related]
3. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.
Moaddel R; Abdrakhmanova G; Kozak J; Jozwiak K; Toll L; Jimenez L; Rosenberg A; Tran T; Xiao Y; Zarate CA; Wainer IW
Eur J Pharmacol; 2013 Jan; 698(1-3):228-34. PubMed ID: 23183107
[TBL] [Abstract][Full Text] [Related]
4. Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat.
Lilius TO; Jokinen V; Neuvonen MS; Niemi M; Kalso EA; Rauhala PV
Br J Pharmacol; 2015 Jun; 172(11):2799-813. PubMed ID: 25297798
[TBL] [Abstract][Full Text] [Related]
5. Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats.
Moaddel R; Sanghvi M; Ramamoorthy A; Jozwiak K; Singh N; Green C; O'Loughlin K; Torjman M; Wainer IW
J Pharm Biomed Anal; 2016 Aug; 127():3-8. PubMed ID: 27017097
[TBL] [Abstract][Full Text] [Related]
6. Interaction between morphine and norketamine enantiomers in rodent models of nociception.
Holtman JR; Crooks PA; Johnson-Hardy J; Wala EP
Pharmacol Biochem Behav; 2008 Oct; 90(4):769-77. PubMed ID: 18582492
[TBL] [Abstract][Full Text] [Related]
7. Neurophysiological response properties of medullary pain-control neurons following chronic treatment with morphine or oxycodone: modulation by acute ketamine.
Viisanen H; Lilius TO; Sagalajev B; Rauhala P; Kalso E; Pertovaara A
J Neurophysiol; 2020 Sep; 124(3):790-801. PubMed ID: 32755331
[TBL] [Abstract][Full Text] [Related]
8. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA
Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852
[TBL] [Abstract][Full Text] [Related]
9. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
[TBL] [Abstract][Full Text] [Related]
10. Spinal coadministration of ketamine reduces the development of tolerance to visceral as well as somatic antinociception during spinal morphine infusion.
Miyamoto H; Saito Y; Kirihara Y; Hara K; Sakura S; Kosaka Y
Anesth Analg; 2000 Jan; 90(1):136-41. PubMed ID: 10624994
[TBL] [Abstract][Full Text] [Related]
11. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (
Highland JN; Morris PJ; Zanos P; Lovett J; Ghosh S; Wang AQ; Zarate CA; Thomas CJ; Moaddel R; Gould TD
J Psychopharmacol; 2019 Jan; 33(1):12-24. PubMed ID: 30488740
[TBL] [Abstract][Full Text] [Related]
12. (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function.
Paul RK; Singh NS; Khadeer M; Moaddel R; Sanghvi M; Green CE; O'Loughlin K; Torjman MC; Bernier M; Wainer IW
Anesthesiology; 2014 Jul; 121(1):149-59. PubMed ID: 24936922
[TBL] [Abstract][Full Text] [Related]
13. The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.
Moaddel R; Sanghvi M; Dossou KS; Ramamoorthy A; Green C; Bupp J; Swezey R; O'Loughlin K; Wainer IW
Pharmacol Res Perspect; 2015 Aug; 3(4):e00157. PubMed ID: 26171236
[TBL] [Abstract][Full Text] [Related]
14. Pregabalin enhances the antinociceptive effect of oxycodone and morphine in thermal models of nociception in the rat without any pharmacokinetic interactions.
Jokinen V; Lilius TO; Laitila J; Niemi M; Rauhala PV; Kalso EA
Eur J Pain; 2016 Feb; 20(2):297-306. PubMed ID: 26031840
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ketamine and three metabolites in Beagle dogs under sevoflurane vs. medetomidine comedication assessed by enantioselective capillary electrophoresis.
Sandbaumhüter FA; Theurillat R; Bektas RN; Kutter APN; Bettschart-Wolfensberger R; Thormann W
J Chromatogr A; 2016 Oct; 1467():436-444. PubMed ID: 27485149
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.
Zhao X; Venkata SL; Moaddel R; Luckenbaugh DA; Brutsche NE; Ibrahim L; Zarate CA; Mager DE; Wainer IW
Br J Clin Pharmacol; 2012 Aug; 74(2):304-14. PubMed ID: 22295895
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
Boronat MA; Olmos G; García-Sevilla JA
Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-relevant concentrations of the ketamine metabolite (2
Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190
[TBL] [Abstract][Full Text] [Related]
19. (2
Kang H; Park P; Han M; Tidball P; Georgiou J; Bortolotto ZA; Lodge D; Kaang BK; Collingridge GL
Brain Neurosci Adv; 2020; 4():2398212820957847. PubMed ID: 33088919
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
